What Quinten does

Quinten (operating commercially as Quinten Health) is a Paris-based AI and data science company founded in 2008 that applies proprietary machine learning algorithms to real-world healthcare data (RWD) and real-world evidence (RWE) to support clinical, regulatory, market access, and corporate development decisions. The firm serves pharmaceutical companies, biotechnology firms, and research institutions, with named engagements spanning Sanofi (across oncology, diabetes, consumer healthcare, and Evidence Generation), Transgene, Gustave Roussy Institute, Léon Bérard Cancer Research Centre, Aetion, Santen Group, Inserm, and EURESIS. Its core offering is an "Evidence Operating System" — an integrated AI platform that combines subgroup discovery algorithms, External Control Arm (ECA) generation, automated extraction from over 200,000 papers and 250+ registries, explainable AI models with interpretability layers, outcomes modeling, and a Rare Disease Framework, delivered through four modular solutions targeting Clinical & Medical, Access & Regulatory, Data & Digital, and Corporate Development teams.

The company's technical differentiators are proprietary subgroup discovery engines, ECA/synthetic control arm methodology, and explainable classification models — capabilities validated through client testimonials referencing regulatory submissions, accelerated approvals, and identification of patient subpopulations with differential treatment response. Quinten operates a B2B consulting and professional services model supplemented by longer-term research partnerships, with revenue derived from project-based engagements and recurring strategic relationships. Go-to-market is exclusively enterprise field sales with direct consultant engagement; pricing is not publicly disclosed.

The firm is founder-led (Alexandre Templier, President and Co-Founder), privately held, and headquartered in central Paris (53 rue de la Chaussée d'Antin, 75009). No external funding rounds, M&A activity, or ownership changes are disclosed in the available data. Marketing relies primarily on content (case studies, publications, news) and a referral network driven by testimonials from executives at major pharmaceutical companies and research institutions.

Name

Quinten

Legal name

Quinten

Website

https://quinten.ai

Company type

Private

Founded year

2008

Operating status

Operating

Short description

Quinten Health is a Paris-based AI consultancy (founded 2008) that applies proprietary machine learning algorithms to real-world healthcare data to support clinical, regulatory, market access, and corporate development decisions for pharmaceutical and life sciences clients.

Ownership category

akta.pro rank

Product category

Healthcare AI Analytics & Real-World Evidence Services

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)

akta.pro secondary industries

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Regulatory Information Management (RIM) & Submission Publishing Software (HLAGAJAL), Pharmacovigilance & Drug Safety Software (HLAGAJAK), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Real-world evidence services
• Healthcare AI consulting
• Clinical data analytics
• Medical text intelligence
• External control arms

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Consulting and Professional Services: Project-based consulting engagements where Quinten Health provides AI and data science expertise to healthcare organizations for evidence generation, clinical strategy, market access, and regulatory submissions. Engagements appear to be tailored solutions for specific client needs across clinical, access, digital, and corporate development functions.
2. Ongoing Research Partnerships: Long-term strategic partnerships with pharmaceutical companies and research institutions for continuous evidence generation support, suggesting potential recurring revenue from established client relationships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Quinten (operating as Quinten Health) provides AI-powered data science consulting and evidence-generation solutions for the healthcare and life sciences industry. Its core offering is an Evidence Operating System that combines machine learning on real-world data, subgroup discovery algorithms, External Control Arm generation, IPD pooling, and explainable AI to help pharmaceutical, biotech, and clinical research clients accelerate clinical decision-making, strengthen regulatory submissions, support market access, and inform corporate development decisions.

Product overview

Quinten Health offers an Evidence Operating System — a unified AI-powered platform for life sciences that combines machine learning, real-world data analytics, and evidence generation capabilities. The platform includes four integrated solution modules: Clinical & Medical Teams (explainable AI, subgroup discovery), Access & Regulatory Teams (External Control Arms, regulatory submissions), Data & Digital Teams (data pooling, hypothesis generation), and Corporate Development (strategic evidence roadmapping). Key product features include External Control Arms for RCT alternatives, IPD Data Pooling for combined evidence, and a Rare Disease Framework for standardized patient identification across regions.

Differentiator

Problem solved

Functional benefit

Products and services

• Evidence Operating System
• External Control Arms (ECA)
• IPD Data Pooling
• Rare Disease Framework
• Solutions for Clinical & Medical Teams
• Solutions for Access & Regulatory Teams
• Solutions for Data & Digital Teams
• Solutions for Corporate Development

Quantifiable outcome

• 67% risk reduction over time (hazard ratio of 0.33 vs. adjusted External Control Arm)
• +4 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• OpenEvidence: OpenEvidence uses AI over the medical literature to surface evidence for clinical decision-making. It competes with Quinten's medical text intelligence and automated extraction capabilities across scientific papers and clinical text.
• Atropos Health: Atropos Health delivers AI-generated real-world evidence and clinical insights from electronic health record data. It is an emerging peer focused on hypothesis generation and physician-level evidence — overlapping with Quinten's medical text intelligence and outcomes modeling.
• Mendel (now Anervea.AI): Mendel applies AI to unstructured clinical text and real-world data for cohort discovery and evidence generation. It overlaps with Quinten's medical text intelligence and subgroup discovery capabilities for pharma and provider use cases.

Broad incumbents

• IQVIA: IQVIA is the largest global provider of advanced analytics, technology solutions and clinical research services to life sciences. Its Real World Evidence and technology offerings compete broadly with Quinten's Evidence Operating System across pharma clients.
• Medidata Solutions: Medidata, a Dassault Systèmes company, provides clinical trial technology including EDC, CTMS and RWE analytics. It competes at the intersection of clinical trial informatics and RWE where Quinten delivers External Control Arms and IPD pooling.
• Evidera (PPD/PPD Clinical Research Services): Evidera provides real-world evidence, health economics and outcomes research for pharma. It is a broad incumbent peer to Quinten in market access, HTA support, and RWE for regulatory submissions.

Direct peers

• Flatiron Health: Flatiron Health provides real-world data and evidence solutions, including External Control Arms and oncology-focused analytics for life sciences. It competes head-to-head with Quinten in ECA generation, clinical evidence, and regulatory-grade RWE for pharma.
• Aetion: Aetion is a leading real-world evidence analytics platform for healthcare and life sciences. It is directly comparable to Quinten — and notably appears as a Quinten customer — operating in the same RWE/RWD analytics category with overlapping pharma and biotech clients.
• Tempus: Tempus combines multi-modal data (clinical, molecular, imaging) with AI to support precision medicine and evidence generation. It overlaps with Quinten's subgroup discovery, patient profiling and outcomes modeling capabilities, especially in oncology.
• TriNetX: TriNetX operates a global health research network leveraging real-world data for clinical trial feasibility, patient identification and evidence generation. It overlaps with Quinten's data & digital and clinical/regulatory solution modules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/quintenfrance
• Facebookfacebook.com/quintenfrance

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quinten